Key Takeaways
- • Inflexion is preparing to sell Celnor, a TICC (technology, information, communications and contact) business with more than 2,750 employees across 60 locations and annual revenues exceeding £300m, to Goldman Sachs Alternatives.
- • Blue Point Capital, Bencis Capital and Gimv are reported to be drawn to the equine healthcare sector, according to the PE Hub Wire commentary.
- • The story is framed as a sector commentary piece, highlighting private equity interest in animal health and services assets.
Summary
According to PE Hub Wire commentary by Nina Lindholm, Inflexion is set to sell Celnor, a business services provider in the TICC space, to Goldman Sachs Alternatives. Celnor employs more than 2,750 people across 60 locations and generates annual revenues exceeding £300m, making it a sizeable asset in the business services segment.
The article also reports that private equity firms Blue Point Capital, Bencis Capital and Gimv have shown interest in equine healthcare, a niche within the broader healthcare sector. The commentary positions these developments as part of a wider pattern of sponsor activity across healthcare and business services, though the primary source provides limited additional detail on deal terms, valuation or timing.
Readers should note that the primary source is a short excerpt, and the specific financial terms of the Celnor transaction were not disclosed in the available text. Further detail on pricing and closing conditions would be needed to assess the deal's full implications for allocators and managers.
The article also reports that private equity firms Blue Point Capital, Bencis Capital and Gimv have shown interest in equine healthcare, a niche within the broader healthcare sector. The commentary positions these developments as part of a wider pattern of sponsor activity across healthcare and business services, though the primary source provides limited additional detail on deal terms, valuation or timing.
Readers should note that the primary source is a short excerpt, and the specific financial terms of the Celnor transaction were not disclosed in the available text. Further detail on pricing and closing conditions would be needed to assess the deal's full implications for allocators and managers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.